[1]王蔚,李学东,刘光旭,等.两种血管内皮生长因子抑制剂对血管内皮细胞功能的抑制作用比较[J].眼科新进展,2019,39(10):920-923.[doi:10.13389/j.cnki.rao.2019.0209]
　WANG Wei,LI Xue-Dong,LIU Guang-Xu,et al.Comparison of inhibitory effects of two vascular endothelial growth factor inhibitors on proliferation of vascular endothelial cells[J].Recent Advances in Ophthalmology,2019,39(10):920-923.[doi:10.13389/j.cnki.rao.2019.0209]
点击复制

两种血管内皮生长因子抑制剂对血管内皮细胞功能的抑制作用比较/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年10期
页码:
920-923
栏目:
实验研究
出版日期:
2019-10-05

文章信息/Info

Title:
Comparison of inhibitory effects of two vascular endothelial growth factor inhibitors on proliferation of vascular endothelial cells
作者:
王蔚; 李学东; 刘光旭; 何燕
100020　北京市，首都医科大学附属北京朝阳医院眼科 （王蔚，李学东）；100069　北京市，首都医科大学公共卫生学院流行病与卫生统计学系（刘光旭，何燕）
Author(s):
WANG Wei; LI Xue-Dong; LIU Guang-Xu; HE Yan
Department of Ophthalmology,Beijing Chaoyang Hospital,Capital Medical University(WANG Wei,LI Xue-Dong),Beijing 100020,China;Department of Epidemiology and Health Statistics,School of Public Health,Capital Medical University (LIU Guang-Xu,HE Yan),Beijing 100069,China
关键词:
tenomodulin; avastin; 人脐静脉内皮细胞; 细胞增殖
Keywords:
tenomodulin; avastin; human umbilical vein endothelial cells; cell proliferation
分类号:
R77
DOI:
10.13389/j.cnki.rao.2019.0209
文献标志码:
A
摘要:
目的　对比tenomodulin（TNMD）和avastin 对血管内皮生长因子（vascular endothelial growth factor,VEGF）诱导的人脐静脉内皮细胞（human umbilical vein endothelial cells,HUVEC）增殖和体外血管样结构形成的抑制作用。方法　将传至3~6代的HUVEC接种于微孔板中贴壁生长，再置于孵箱中培养6 h，分别加入不同剂量VEGF处理24 h,MTT法测量细胞增殖能力,筛选促进细胞最大增殖作用的VEGF剂量A。将HUVEC分别加入A剂量的VEGF+不同剂量（0.25 mg·L-1、0.50 mg·L-1、1.00 mg·L-1、2.00 mg·L-1）的TNMD或avastin置于孵箱中培养24 h,MTT法检测TNMD和avastin对VEGF诱导的HUVEC增殖抑制的差异。基质胶体实验检测细胞体外血管形成的形态和长度：实验分为4组，A组为阳性对照；B组添加VEGF;C组添加 VEGF和 avastin;D组添加VEGF和TNMD，共焦显微镜下观察细胞形态，图像处理分析软件量化分析毛细血管样结构的差异。结果　MTT在490 nm波长处测定吸光值（A值）检测细胞增殖，结果显示，相同药物浓度时TNMD的A值均明显低于avastin的A值（均为P<0.01）。基质胶体实验结果显示，D组的毛细血管样结构破坏明显；A组、B组、C组和D组细胞总长度分别为（7422±311）μm、（9369±121）μm、（6499±258）μm、（5292±137）μm，两两相比差异均有统计学意义（均为P<0.05）。结论　TNMD比avastin对体外培养的HUVEC增殖具有更强的抑制作用。
Abstract:
Objective　To explore the inhibitory effect of tenomodulin (TNMD) and avastin on human umbilical vein endothelial cells (UVECs) proliferation and capillary-like morphogenesis in vitro induced by vascular endothelial growth factor (VEGF).Methods　HUVECs between passages 3 and 6 were inoculated into microplates for growth,and then placed in an incubator for 6 hours.Different doses of VEGF were added for 24 hours.MTT assay was used to measure cell proliferation and screen out the appropriate VEGF dose (A) for the maximum proliferation effect.A dose of VEGF + different doses (0.25 mg·L"-1,0.50 mg·L-1,1.00 mg·L-1,200.00 mg·L-1) of TNMD or avastin was added into HUVEC in the incubator for 24 hours of culture.MTT assay was used to detect the difference of VEGF-induced inhibition of HUVEC proliferation by TNMD and avastin.The length and morphology of capillary-like structures formed by HUVEC was evaluated by Matrigel tube formation assay.Cells were divided into the positive control (A group),A+ VEGF group (B group),B+ avastin group (C group),B+TNMD group (D group).Cell morphology was observed under confocal microscopy,and image processing analysis software was used to quantify the differences in capillary-like structures.Results　MTT measured the absorbance (A value) at 490 nm to detect cell proliferation.The results showed that the A value of TNMD was significantly lower than that of avastin at the same VEGF concentration (both P<0.01).The results of matrix colloidal experiment showed that the capillary-like structure of D group was destroyed obviously;the total length of cells in A group,B group,C group and D group were (7422±311)μm,(9369±121)μm,(6499±258)μm,(5292±137)μm,and the difference between the two groups was statistically significant (all P<0.05).Conclusion　TNMD has a stronger inhibitory effect on angiogenesis in vitro than avastin.

参考文献/References:

［1］　BERG K,PEDERSEN T R,SANDVIK L,BRAGADTTIR R.Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol［J］.Ophthalmology,2015,122(1):146-152.
［2］　SOLOMON S D,LINDSLEY K,VEDULA S S,KRZYSTOLIK M G,HAWKINS B S.Anti-vascular endothelial growth factor for neovascular age-related macular degeneration［J］.Cochrane Database Syst Rev,2014,8:CD005139.
［3］　MOJA L,LUCENTEFORTE E,KWAG K H,BERTELE V,CAMPOMORI A,CHAKRAVARTHY U,et al.Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration［J］.Cochrane Database Syst Rev,2014,9:CD011230.
［4］　KIM M M,UMEMURA Y,LEUNG D.Bevacizumab and glioblastoma:past,present,and future directions［J］.Cancer J,2018,24(4):180-186.
［5］　BROWN D M,MICHELS M,KAISER P K,HEIER J S,SY J P,LANCHULEY T,et al.Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration:two-year results of the ANCHOR study［J］.Ophthalmology,2009,116(1):57-65.
［6］　ZHAI Y,NI J,JIANG G W,LU J,XING L,LINCOLN C,et al.VEGI,a novel cytokine of the tumor necrosis factor family,is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo［J］.FASEB J,1999,13(1):181-189.
［7］　OSHIMA Y,SHUKUNAMI C,HONDA J,NISHIDA K,TASHIRO F,MIYAZAKI J,et al.Expression and localization of tenomodulin,a transmembrane type chondromodulin-I-related angiogenesis inhibitor,in mouse eyes［J］.Invest Ophthalmol Vis Sci,2003,44(5):1814-1823.
［8］　DOCHEVA D,HUNZIKER E B,FASSLER R,BRANDAU O.Tenomodulin is necessary for tenocyte proliferation and tendon maturation［J］.Mol Cell Biol,2005,25(2):699-705.
［9］　OSHIMA Y,SATO K,TASHIRO F,MIYAZAKI J,NISHIDA K,HIRAKI Y,et al.Anti-angiogenic action of the C-terminal domain of tenomodulin that shares homology with chondromodulin-I［J］.J Cell Sci,2004,117(Pt 13):2731-2744.
［10］　SHUKUNAMI C,OSHIMA Y,HIRAKI Y.Chondromodulin-I and tenomodulin:a new class of tissue-specific angiogenesis inhibitors found in hypovascular connective tissues［J］.Biochem Biophys Res Commun,2005,333(2):299-307.
［11］　FUNAKI H,SAWAGUCHI S,YAOEDA K,KOYAMA Y,YAOITA E,FUNAKI S,et al.Expression and localization of angiogenic inhibitory factor,chondromodulin-I,in adult rat eye［J］.Invest Ophthalmol Vis Sci,2001,42(6):1193-1200.
［12］　WANG W,OSHIMA Y,TANO Y.Inhibitory effect of tenomodulin protein on proliferation of vascular endothelial cells［J］.Chin J Exp Ophthalmol,2010,28(7):617-621.
王蔚，大岛佑介，田野保雄.Tenomodulin 蛋白对血管内皮细胞增生的抑制作用［J］.中华实验眼科杂志，2010,28(7)：617-621.
［13］　WANG W,OSHIMA Y,TANO Y.Anti-angiogenic effect of the transmemberane protein (Ten omodulin) on retinal neovascularization in a mouse model［J］.Chin J Exp Ophthalmol,2010,28(2):114-118.
王蔚，大岛佑介，田野保雄.Tenomodulin 抑制氧诱导视网膜病变小鼠模型新生血管形成的研究［J］.中华实验眼科杂志，2010,28(2):114-118.
［14］　ALEXANDROV V P,NAIMOV S I.A prospectus of Tenomodulin［J］.Folia Med,2016,58(1):19-27.
［15］　BRANDAU O,MEINDL A,FASSLER R,ASZODI A.A novel gene,tendin,is strongly expressed in tendons and ligaments and shows high homology with chondromodulin-I［J］.Dev Dyn,2001,221(1):72-80.
［16］　YAMANA K,WADA H,TAKAHASHI Y,SATO H,KASAHARA Y,KIYOKI M.Molecular cloning and characterization of CHM1L;a novel membrane molecule similar to chondromodulin-I［J］.Biochem Biophys Res Commun,2001,280(4):1101-1106.
［17］　WANG W,LI Z Q,SATO T,OSHIMA Y.Tenomudulin inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy［J］.Int J Mol Sci,2012,13:15373-15386.

相似文献/References:

[1]李秀云 李聪伶 王俊 李娜 赵岩松.Avastin联合周边视网膜冷冻术治疗晚期新生血管性青光眼[J].眼科新进展,2012,32(12):000.
[2]赵倩 金学民.Avastin联合黄斑格栅样光凝治疗糖尿病黄斑水肿的临床研究[J].眼科新进展,2013,33(2):000.
[3]周楠 黄潇 李玉珍 程金伟 蔡季平.Avastin-壳聚糖纳米粒的制备[J].眼科新进展,2012,32(2):000.
[4]魏光杰,何佃菊.532nm绿激光格栅样光凝联合球内注药治疗糖尿病视网膜病变黄斑水肿[J].眼科新进展,2014,34(8):779.[doi:10.13389/j.cnki.rao.2014.0215]
　WEI Guang-Jie,HE Dian-Ju.532 run green grid laser photocoagulation combined with intravitreal Avastin injection for diabetic retinopathy macular edema[J].Recent Advances in Ophthalmology,2014,34(10):779.[doi:10.13389/j.cnki.rao.2014.0215]
[5]李戴弟,高云霞,潘玲珍,等.Lucentis和Avastin治疗激光诱导恒河猴脉络膜新生血管模型的作用[J].眼科新进展,2016,36(5):423.[doi:10.13389/j.cnki.rao.2016.0113]
　LI Dai-Di,GAO Yun-Xia,PAN Ling-Zhen,et al.Therapeutic effects of Avastin and Lucentis on laser-induced choroidal neovascularization in thesus monkeys[J].Recent Advances in Ophthalmology,2016,36(10):423.[doi:10.13389/j.cnki.rao.2016.0113]

备注/Memo

备注/Memo:
首都医科大学基础-临床科研合作课题（编号：13JL13）
更新日期/Last Update: 2019-10-12